Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Provided By GlobeNewswire
Last update: Sep 5, 2025
TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.
Read more at globenewswire.com
